Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors

Clinical Lymphoma, Myeloma and Leukemia

Volumn 17, Issue 8, 2017, Pages 471-478

  Gay, Francesca ^a   D'Agostino, Mattia ^a   Giaccone, Luisa ^a   Genuardi, Mariella ^a   Festuccia, Moreno ^a   Boccadoro, Mario ^a   Bruno, Benedetto ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

CAR T cells; Checkpoint inhibitors; Chimeric antigen receptor; Immune oncology; Multiple myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; B CELL MATURATION ANTIGEN; CD19 ANTIGEN; CHECKPOINT INHIBITOR; CHIMERIC ANTIGEN RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; HYBRID PROTEIN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; DRUG EFFICACY; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; METABOLISM; PROCEDURES; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; CTLA-4 ANTIGEN; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTE SUBSETS;

EID: 85021787441     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2017.06.014     Document Type: Review

References (81)

1. Morgan, G.J., Kaiser, M.F., How to use new biology to guide therapy in multiple myeloma. Hematology Am Soc Hematol Educ Program 2012 (2012), 342–349.
2. Zelle-Rieser, C., Thangavadivel, S., Biedermann, R., et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol, 9, 2016, 116.
3. Dranoff, G., Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4 (2004), 11–22.
4. Chang, M.-H., Cancer prevention by vaccination against hepatitis B. Recent Results Cancer Res 181 (2009), 85–94.
5. Kenter, G.G., Welters, M.J.P., Valentijn, A.R.P.M., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361 (2009), 1838–1847.
6. Finn, O.J., Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 23:suppl 8 (2012), viii6–viii9.
7. Schreiber, R.D., Old, L.J., Smyth, M.J., Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331 (2011), 1565–1570.
8. Zou, W., Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6 (2006), 295–307.
9. Ostrand-Rosenberg, S., Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 18 (2008), 11–18.
10. Kim, P.S., Ahmed, R., Features of responding T cells in cancer and chronic infection. Curr Opin Immunol 22 (2010), 223–230.
11. Romano, A., Conticello, C., Cavalli, M., et al. Immunological dysregulation in multiple myeloma microenvironment. Biomed Res Int, 2014, 2014, 198539.
12. Sotomayor, E.M., Borrello, I., Rattis, F.M., et al. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 98 (2001), 1070–1077.
13. Brown, R.D., Pope, B., Murray, A., et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 98 (2001), 2992–2998.
14. Brimnes, M.K., Svane, I.M., Johnsen, H.E., Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma. Clin Exp Immunol 144 (2006), 76–84.
15. Nishikawa, H., Sakaguchi, S., Regulatory T cells in tumor immunity. Int J Cancer 127 (2010), 759–767.
16. Rodriguez, P.C., Quiceno, D.G., Zabaleta, J., et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 64 (2004), 5839–5849.
17. Veillette, A., Guo, H., CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol 88 (2013), 168–177.
18. Cruz-Munoz, M.-E., Dong, Z., Shi, X., Zhang, S., Veillette, A., Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function. Nat Immunol 10 (2009), 297–305.
19. Lonial, S., Dimopoulos, M., Palumbo, A., et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373 (2015), 621–631.
20. Jakubowiak, A., Offidani, M., Pégourie, B., et al. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory multiple myeloma. Blood 127 (2016), 2833–2840.
21. Lin, P., Owens, R., Tricot, G., Wilson, C.S., Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 121 (2004), 482–488.
22. Santonocito, A.M., Consoli, U., Bagnato, S., et al. Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. Leuk Res 28 (2004), 469–477.
23. de Weers, M., Tai, Y.-T., van der Veer, M.S., et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 186 (2011), 1840–1848.
24. Overdijk, M.B., Verploegen, S., Bögels, M., et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 7 (2015), 311–321.
25. Krejcik, J., Casneuf, T., Nijhof, I., et al. Immunomodulatory effects and adaptive immune response to daratumumab in multiple myeloma. Blood, 126, 2015 (abstract 3037).
26. Lokhorst, H.M., Plesner, T., Laubach, J.P., et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 373 (2015), 1207–1219.
27. Lonial, S., Weiss, B.M., Usmani, S.Z., et al. Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius). 2015 ASCO Annual Meeting | Abstracts | Meeting Library ASCO, 2015 (abstract LBA8512).
28. Palumbo, A., Chanan-Khan, A., Weisel, K., et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375 (2016), 754–766.
29. Dimopoulos, M.A., Oriol, A., Nahi, H., et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375 (2016), 1319–1331.
30. Görgün, G., Calabrese, E., Soydan, E., et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 116 (2010), 3227–3237.
31. LeBlanc, R., Hideshima, T., Catley, L.P., et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103 (2004), 1787–1790.
32. Neuber, B., Herth, I., Tolliver, C., et al. Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma. J Immunol 187 (2011), 1047–1056.
33. Borrello, I., Marrow infiltrating lymphocytes and vaccines in myeloma. Blood, 128, 2016 (abstract SCI-35).
34. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2012), 252–264.
35. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
36. Bashey, A., Medina, B., Corringham, S., et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 113 (2009), 1581–1588.
37. Lesokhin, A.M., Ansell, S.M., Armand, P., et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol 34 (2016), 2698–2704.
38. Mateos, M.-V., Orlowski, R.Z., Siegel, D.S.D., et al. Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis. 2016 ASCO Annual Meeting | Abstracts | Meeting Library ASCO, 34, 2016 (abstract 8010).
39. Badros, A.Z., Hyjek, E., Ma, N., et al. Pembrolizumab in combination with pomalidomide and dexamethasone for relapsed/refractory multiple myeloma (RRMM). Blood, 128, 2016 (abstract 490).
40. Hodi, F.S., O'Day, S.J., McDermott, D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
41. Tivol, E.A., Borriello, F., Schweitzer, A.N., et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3 (1995), 541–547.
42. Walker, L.S.K., Sansom, D.M., The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 11 (2011), 852–863.
43. Allison, J.P., CD28-B7 interactions in T-cell activation. Curr Opin Immunol 6 (1994), 414–419.
44. Yousef, S., Marvin, J., Steinbach, M., et al. Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. Blood Cancer J, 5, 2015, e285.
45. Keir, M.E., Butte, M.J., Freeman, G.J., Sharpe, A.H., PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26 (2008), 677–704.
46. Nishimura, H., Nose, M., Hiai, H., Minato, N., Honjo, T., Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11 (1999), 141–151.
47. Fife, B.T., Bluestone, J.A., Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 224 (2008), 166–182.
48. Buchbinder, E.I., Desai, A., CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 39 (2016), 98–106.
49. Nguyen, L.T., Ohashi, P.S., Clinical blockade of PD1 and LAG3—potential mechanisms of action. Nat Rev Immunol 15 (2015), 45–56.
50. Liu, J., Hamrouni, A., Wolowiec, D., et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110 (2007), 296–304.
51. Hallett, W.H.D., Jing, W., Drobyski, W.R., Johnson, B.D., Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol Blood Marrow Transplant 17 (2011), 1133–1145.
52. Rozali, E.N., Hato, S.V., Robinson, B.W., Lake, R.A., Lesterhuis, W.J., Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol, 2012, 2012, 656340.
53. Görgün, G., Samur, M.K., Cowens, K.B., et al. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin Cancer Res 21 (2015), 4607–4618.
54. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
55. Ansell, S.M., Lesokhin, A.M., Borrello, I., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372 (2015), 311–319.
56. Funt, S.A., Page, D.B., Cattry, D., et al. The long PD-1 receptor binding kinetics of nivolumab may increase efficacy of subsequent therapy in relapsed and refractory multiple myeloma patients. Blood, 126, 2015 (abstract 3057).
57. Benson, D.M., Checkpoint inhibition in myeloma. Hematology Am Soc Hematol Educ Program 2016 (2016), 528–533.
58. Benson, D.M., Caligiuri, M.A., Killer immunoglobulin-like receptors and tumor immunity. Cancer Immunol Res 2 (2014), 99–104.
59. Benson, D.M., Hofmeister, C.C., Padmanabhan, S., et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 120 (2012), 4324–4333.
60. Carbone, E., Neri, P., Mesuraca, M., et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 105 (2005), 251–258.
61. Nijhof, I.S., Lammerts van Bueren, J.J., van Kessel, B., et al. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica 100 (2015), 263–268.
62. Korde, N., Carlsten, M., Lee, M.-J., et al. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica 99 (2014), e81–e83.
63. Benson, D.M., Cohen, A.D., Jagannath, S., et al. A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma. Clin Cancer Res 21 (2015), 4055–4061.
64. Urba, W.J., Longo, D.L., Redirecting T cells. N Engl J Med 365 (2011), 754–757.
65. Gschweng, E., De Oliveira, S., Kohn, D.B., Hematopoietic stem cells for cancer immunotherapy. Immunol Rev 257 (2014), 237–249.
66. Grupp, S.A., Kalos, M., Barrett, D., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368 (2013), 1509–1518.
67. Brentjens, R.J., Davila, M.L., Riviere, I., et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med, 5, 2013, 177ra38.
68. Porter, D.L., Hwang, W.-T., Frey, N.V., et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med, 7, 2015, 303ra139.
69. Tembhare, P.R., Yuan, C.M., Venzon, D., et al. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res 38 (2014), 371–376.
70. Hajek, R., Okubote, S.A., Svachova, H., Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. Br J Haematol 163 (2013), 551–564.
71. Garfall, A.L., Maus, M.V., Hwang, W.-T., et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med 373 (2015), 1040–1047.
72. Garfall, A.L., Stadtmauer, E.A., Maus, M.V., et al. Pilot study of anti-CD19 chimeric antigen receptor T cells (CTL019) in conjunction with salvage autologous stem cell transplantation for advanced multiple myeloma. Blood, 128, 2016 (abstract 974).
73. Ali, S.A., Shi, V., Maric, I., et al. T cells expressing an anti-B-cell-maturation-antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128 (2016), 1688–1700.
74. Cohen, A.D., Garfall, A.L., Stadtmauer, E.A., et al. B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) for multiple myeloma (MM): initial safety and efficacy from a phase I study. Blood, 128, 2016 (abstract 1147).
75. Berdeja, J.G., Lin, Y., Raje, N., et al. Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma. Eur J Cancer, 69, 2016, S5.
76. Wijdenes, J., Vooijs, W.C., Clément, C., et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 94 (1996), 318–323.
77. Heffner, L.T., Jagannath, S., Zimmerman, T.M., et al. BT062, an antibody-drug conjugate directed against CD138, given weekly for 3 weeks in each 4 week cycle: safety and further evidence of clinical activity. Blood, 120, 2015 (abstract 4042).
78. Vera, J., Savoldo, B., Vigouroux, S., et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 108 (2006), 3890–3897.
79. Luptakova, K., Avigan, D., Immune therapy in multiple myeloma. Clin Adv Hematol Oncol 13 (2015), 767–775.
80. Brudno, J.N., Kochenderfer, J.N., Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127 (2016), 3321–3330.
81. Garfall, A.L., Lancaster, E., Stadtmauer, E.A., et al. Posterior reversible encephalopathy syndrome (PRES) after infusion of anti-Bcma CAR T cells (CART-BCMA) for multiple myeloma: successful treatment with cyclophosphamide. Blood, 128, 2016 (abstract 5702).